Aiming High: Prostate-specific Membrane Antigen Expression in Treatment-naïve Prostate Cancer.
作者信息
Bakht Martin K, Beltran Himisha
机构信息
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
出版信息
Eur Urol. 2024 Dec;86(6):588-590. doi: 10.1016/j.eururo.2024.09.033. Epub 2024 Oct 11.
Abstract
摘要
相似文献
1
Aiming High: Prostate-specific Membrane Antigen Expression in Treatment-naïve Prostate Cancer.志存高远：未经治疗的前列腺癌中前列腺特异性膜抗原的表达
Eur Urol. 2024 Dec;86(6):588-590. doi: 10.1016/j.eururo.2024.09.033. Epub 2024 Oct 11.
2
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描与常规成像在初治中高危前列腺癌分期中的比较：一项回顾性单中心研究。
Eur Urol Oncol. 2022 Oct;5(5):544-552. doi: 10.1016/j.euo.2020.08.012. Epub 2020 Sep 18.
3
Consecutive Prostate-Specific Membrane Antigen (PSMA) and Antigen Receptor (AR) PET Imaging Shows Positive Correlation with AR and PSMA Protein Expression in Primary Hormone-Naïve Prostate Cancer.连续前列腺特异性膜抗原 (PSMA) 和抗原受体 (AR) PET 成像与原发性激素初治前列腺癌中的 AR 和 PSMA 蛋白表达呈正相关。
J Nucl Med. 2023 Jun;64(6):863-868. doi: 10.2967/jnumed.122.264981. Epub 2023 Jan 19.
4
Treatment strategies and outcomes in a long-term registry study of patients with high-risk metastatic hormone-naïve prostate cancer in Japan: An interim analysis of the J-ROCK study.在日本一项针对高危转移性去势敏感性前列腺癌患者的长期登记研究中：J-ROCK 研究的中期分析。
Int J Urol. 2022 Sep;29(9):1061-1070. doi: 10.1111/iju.14993. Epub 2022 Aug 26.
5
Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.未经化疗的转移性去势抵抗性前列腺癌且基线前列腺特异性抗原低的男性患者使用恩扎卢胺与安慰剂治疗的临床结局对比。
J Urol. 2017 Dec;198(6):1324-1332. doi: 10.1016/j.juro.2017.07.071. Epub 2017 Jul 20.
6
Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer.未经治疗的前列腺癌中前列腺特异性膜抗原的分子特征
Eur Urol. 2024 Dec;86(6):579-587. doi: 10.1016/j.eururo.2024.09.005. Epub 2024 Sep 17.
7
Prospective evaluation of magnetic resonance imaging guided in-bore prostate biopsy versus systematic transrectal ultrasound guided prostate biopsy in biopsy naïve men with elevated prostate specific antigen.对前列腺特异性抗原升高的初诊男性患者，磁共振成像引导下的孔内前列腺活检与系统经直肠超声引导下前列腺活检的前瞻性评估。
J Urol. 2014 Nov;192(5):1374-9. doi: 10.1016/j.juro.2014.05.090. Epub 2014 May 24.
8
Assessment of the therapeutic efficacy of [Lu]Lu-PSMA-X compared to taxane chemotherapy in taxane-chemo-naïve patients with metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.在初治转移性去势抵抗性前列腺癌患者中，[镥]镥 - PSMA - X与紫杉烷化疗的治疗效果评估：一项系统评价和荟萃分析
Eur J Nucl Med Mol Imaging. 2025 Feb;52(3):936-954. doi: 10.1007/s00259-024-06932-2. Epub 2024 Oct 25.
9
Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?镥前列腺特异性膜抗原放射性配体治疗用于仅有淋巴结转移的前列腺癌患者时，是否应更早使用？
Investig Clin Urol. 2021 Nov;62(6):650-657. doi: 10.4111/icu.20210097.
10
A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study).醋酸阿比特龙在未经化疗的日本转移性去势抵抗性前列腺癌男性患者中的2期试验（JPN - 201研究）
Jpn J Clin Oncol. 2014 Dec;44(12):1216-26. doi: 10.1093/jjco/hyu149. Epub 2014 Oct 15.
本文引用的文献
1
Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer.未经治疗的前列腺癌中前列腺特异性膜抗原的分子特征
Eur Urol. 2024 Dec;86(6):579-587. doi: 10.1016/j.eururo.2024.09.005. Epub 2024 Sep 17.
2
Sequential [Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study.LuLu-PSMA-617 序贯治疗与多西他赛治疗转移性去势敏感性前列腺癌患者的疗效比较（UpFrontPSMA）：一项多中心、开放标签、随机、Ⅱ期临床研究。
Lancet Oncol. 2024 Oct;25(10):1267-1276. doi: 10.1016/S1470-2045(24)00440-6. Epub 2024 Sep 15.
3
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer.前列腺癌中前列腺特异性膜抗原（PSMA）表达、调控及异质性的生物学决定因素
Nat Rev Urol. 2025 Jan;22(1):26-45. doi: 10.1038/s41585-024-00900-z. Epub 2024 Jul 8.
4
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer.雄激素受体阳性和雄激素受体阴性转移性前列腺癌中前列腺特异性膜抗原异质性和调控的全景。
Nat Cancer. 2023 May;4(5):699-715. doi: 10.1038/s43018-023-00539-6. Epub 2023 Apr 10.
5
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.PSMA 和 FDG-PET 作为预测和预后生物标志物，用于比较 [Lu]Lu-PSMA-617 与卡巴他赛治疗转移性去势抵抗性前列腺癌（TheraP）：一项随机、开放标签、2 期临床试验的生物标志物分析。
Lancet Oncol. 2022 Nov;23(11):1389-1397. doi: 10.1016/S1470-2045(22)00605-2. Epub 2022 Oct 16.
6
Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09/10 randomized clinical trial.在根治性前列腺切除术后未接受激素治疗的患者中接受挽救性放疗时，验证 Decipher 基因组分类器- SAKK 09/10 随机临床试验的辅助研究。
Ann Oncol. 2022 Sep;33(9):950-958. doi: 10.1016/j.annonc.2022.05.007. Epub 2022 May 28.
7
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.镥 177-PSMA-617 治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.
8
Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity.研究 PSMA 靶向放射性配体治疗的疗效与细胞 PSMA 水平和肿瘤内 PSMA 异质性的关系。
Clin Cancer Res. 2020 Jun 15;26(12):2946-2955. doi: 10.1158/1078-0432.CCR-19-1485. Epub 2020 Jan 13.
9
Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer.极低前列腺特异性抗原水平与高级别前列腺癌男性患者癌症特异性死亡增加的关联。
Cancer. 2016 Jan 1;122(1):78-83. doi: 10.1002/cncr.29691. Epub 2015 Sep 15.
10
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.转移性激素敏感性前列腺癌的化学激素疗法
N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5.
Zotero 插件